Organon & Co.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how the company performed in the second quarter and helps investors understand its business health.
Official detailed financial statements let investors see revenue, expenses, and assets to evaluate company value.
Shareholders voted to combine with Sun Pharmaceutical, which will fundamentally change the company's ownership.
The deal signed April 26, 2026 is moving forward, which affects what happens to shareholders' investments.
More shares available for employee rewards can dilute existing shareholders' ownership stakes over time.
Quarterly financial details show early-year performance and help track company progress through the year.
First-quarter earnings announcement reveals how well the company started the year and its financial trends.
Stocky reads Organon & Co.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Organon & Co.'s most recent tracked filing was a 8-K on 31 Jul 2026: Released Q2 2026 financial results with non-GAAP metrics.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.